U.S. top court rejects Amgen over cholesterol medication patent fight
WASHINGTON (Reuters) – Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. FILE PHOTO: An Amgen sign is seen at… Read More »